Ardent Health Partners ARDT Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Ardent Health Partners in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: Ardent Health Partners’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ardent Health Partners's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ardent Health Partners's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
- Ardent Health Partners (ARDT) reported cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation of -$99.91M in Q1 2026.
- How has Ardent Health Partners's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation changed year-over-year?
- Ardent Health Partners's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation decreased by 61.8% year-over-year, from -$61.74M to -$99.91M.
- What is the long-term trend for Ardent Health Partners's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
- Over 2 years (2022 to 2025), Ardent Health Partners's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation has grown at a -23.6% compound annual growth rate (CAGR), from -$262.11M to $152.82M.
- What does cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation mean?
- Represents the net change in the total balance of cash, cash equivalents, and restricted cash over a specific reporting period. This metric reflects the company's overall liquidity movement, incorporating cash flows from operating, investing, and financing activities. It is a primary indicator of the company's ability to manage its cash position and meet short-term financial obligations.